Contact this trialFirst, we need to learn more about you.
PARP inhibitor
Olaparib + Temozolomide for Uterine Leiomyosarcoma
Recruiting1 awardPhase 2 & 3
Loveland, Colorado
This trial is comparing the effectiveness of a combination treatment using olaparib and temozolomide to the common chemotherapy drugs trabectedin or pazopanib. The trial is for patients
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service